Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Abstract Cyclic high-dose testosterone administration, known as bipolar androgen therapy (BAT), is a treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we report the results of a multicenter, single arm Phase 2 study (NCT03554317) enrolling 45 patient...

詳細記述

書誌詳細

出版年:	Nature Communications
主要な著者:	Mark C. Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A. Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A. Carducci, Channing J. Paller, Catherine H. Marshall, Mario A. Eisenberger, David E. Sanin, Srinivasan Yegnasubramanian, Carolina Gomes-Alexandre, Busra Ozbek, Tracy Jones, Angelo M. De Marzo, Samuel R. Denmeade, Emmanuel S. Antonarakis
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2024-01-01
オンライン･アクセス:	https://doi.org/10.1038/s41467-023-44514-2